Connect with us

BUSINESS

GreenGro Technologies, Inc. Common Stock (OTCMKTS: GRNH) Launches New Hemp-Infused Product Line Under Greengro Brand

Published

on

GreenGro Technologies, Inc. Common Stock (OTCMKTS: GRNH) recently announced the launch of its much-awaited product line of hemp-infused topicals, tinctures, oil, and capsules. The launch will focus on the product range that contains the main psychoactive component, tetrahydrocannabinol (THC), found in cannabis. The newly launched products under GreenGro Brand will be available online through its eCommerce platform and its distributor network. In addition, GreenGro also announced two new distribution agreements with a network of pharmacies, pain management clinics, and dispensaries for marketing and selling the new product line. 

Operational focus and management comment

GreenGro is committed to creating shareholder value by maximizing profit by licensing its eco-friendly technological solutions for the hemp and cannabis industry. The company’s operating divisions GenoBreeding, Cannabis Ventures, and CBD Ventures, allows it to operate in the cultivation, extraction, production, and retail aspects of the market. In addition, GreenGro’s three business divisions allow an efficient, synergistic, and highly profitable business model by leveraging each other’s strengths. 

Tom Schaefer, Chief Executive Officer of CBD Ventures, a wholly-owned subsidiary of GreenGro, expressed that the recent launch underlines the company’s commitment to continually offer new and innovative hemp-infused products with various delivery methods. Additionally, these products will be available through a network of independent retailers in Arizona and California and contribute to future revenue growth.

Operational update and expansion plans

GreenGro recently announced a strategic multi-year marketing and distribution agreement for Neurofarms’ latest products and formulations across national and international markets. Neurofarms is a San Diego-based developer and provider of top-grade medicinal cannabis products and cannabinoid medicines. GreenGro will resume the build-out of its cannabis dispensary located near Palm Springs in Riverside County, in Cathedral City, California. The announcement follows the recent approval of Conditional Use Permits for the manufacturing, distribution, and delivery licenses. The dispensary will be an integral part of the company’s regional expansion strategy in Southern California. GreenGro recently appointed Charles Garavitt as its Chief International Officer, responsible for overseeing a global market presence primarily through a franchise business model.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Namaste Technologies Inc (OTCMKTS: NXTTF) Subsidiary Will Be The Exclusive Distributor For Rapid Dose Therapeutics’ Branded Cannabis Products Across Canada

Published

on

Namaste Technologies Inc’s (OTCMKTS: NXTTF) subsidiary CannMart Inc. entered a Master Distribution Agreement with Rapid Dose Therapeutics Corp. to distribute their innovative cannabis brands across Canada. The products include QuickStrip™ and QuickSips™, a 10 mg Tetrahydrocannabinol (THC) sublingual oral dissolving strip and 100% biodegradable THC-lined drinking straw. QuickStrip™ quickly delivers the primary psychoactive compound in cannabis into the bloodstream resulting in rapid onset of action bypassing first-pass metabolism. QuickSips™, made from sugarcane fibers, quickly dissolves in hot or cold beverages to deliver a precise dose in a few sips. 

CEO comments about the agreement

Meni Morim, Chief Executive Officer of Namaste Technologies, expressed excitement to sign the agreement with Rapid Dose Therapeutics to distribute their innovative cannabis product range. The QuickStrip™ and QuickSips™ present the addition of a new category of products in line with the company’s continuing focus to build a broad spectrum of cannabis products leveraging both conventional and newer delivery platforms. Additionally, CannMart receives many requests from vendors across North America to host their products on the CannMart.com marketplace platform. As a result, its SKU count now stands at approximately 700. The CEO expressed that the partnership with RDT will be successful and a contributor to the company’s growth objectives.

Operational focus and corporate update

Namaste Technologies serves Canadian medical customers with a diverse range of cannabis products from the licensed cultivators. The company also provides U.S. customers with access to CBD and smoking accessories. Its cutting-edge technology and continuous innovation address local needs with intelligent solutions in the rapidly growing cannabis industry. Its subsidiary CannMart recently received the first purchase orders from Manitoba and Saskatchewan for its recreational house brand ‘Roilty’ Concentrates. Roilty will be positioned as a premium, legacy-inspired brand with a product range consisting of distillate vapes, shatter, crumble, live resin, and wax in the coming quarters.

Rapid Dose Therapeutics is a life sciences company focused on innovative, proprietary drug delivery technologies to improve medicinal outcomes. Its primary work revolves around clinical research and product development across nutraceutical, pharmaceutical, and cannabis industries. RDT’s innovative healthcare solutions aim to improve the quality of life for humans, animals, and plants. 

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Sunniva Inc (OTCMKTS: SNNVF) Announces Implementation Of Plan Of Arrangement, Arbitration, And Financial Update

Published

on

Tetra Bio Pharma

Sunniva Inc (OTCMKTS: SNNVF) announced that effective mid-June, the company and its Canadian subsidiaries had implemented the Amended and Consolidated Plan of Compromise and Arrangement Sanction Order on February 12, 2021, by the Supreme Court of British Columbia. The Plan of Arrangement also included issuing an aggregate of 755.81 million common shares of the company. Under the Sanction Order, the Petitioners – Sunniva and its Canadian subsidiaries – were discharged and released from the CCAA proceedings. In addition, Alvarez & Marsal Inc., a consulting firm with more than 35 years of client service experience, was also discharged and released from its duties about the Petitioners.

The company reported that the audits of its financial statements for FY2019 and FY2020 are under process and will complete before the anticipated schedule. The draft financial package for FY2019 is under internal review, and some work on the FY2020 audit has been carried in tandem to gain efficiency. Work on the audits of both the financial years is likely to be completed by the end of July 2021. 

Update on arbitration in Southern California

CP Logistics, LLC (CPL), Sunniva’s wholly-owned subsidiary, continues to be engaged in arbitration with the owner of the California glasshouse, Bobs LLC, regarding its rights as a tenant. This arbitration underlines a Conditional Build to Suite Lease (October 2017) and a Subordinated Non-Disturbance and Attornment Agreement (March 2018). On July 2, 2021, the parties to the arbitration held a Preliminary Conference Call with the Tribunal, JAMS Arbitration, wherein they agreed to the initial document exchange schedule. A second Call has been scheduled for August 13, 2021, to set interim deadlines for discovery, other pre-hearing preparations, and a date for a hearing.

 Current information on the financial state

Sunniva currently has $1.32 million of cash, with an incremental $245,000 from retainer and tax refunds expected by 3Q2021. As a result, it would increase the net cash on hand to $1.6 million. The company reported a total expenditure of $4.9 million over the past 12-month period, including administrative and legal expenses associated with CCAA Proceedings. The management believed that Sunniva has sufficient cash to fund administrative and arbitration expenses through 1Q2022. In addition, the company has submitted an insurance claim for reimbursement of arbitration-related expenses. 

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Khiron Life Sciences Corp (OTCMKTS: KHRNF) Accelerating Its Expansion and Presence In Mexico and Brazil

Published

on

Khiron Life Sciences Corp (OTCMKTS: KHRNF) has announced the successful completion of its first medical cannabis sale in Brazil. The company plans to leverage its clinical distribution and production assets in Latin America plus marketing contracts with pharmaceutical distributors to expand its presence in Brazil, where there is a market of more than 200 million people.

Khiron enhancing its presence in Brazil

The company’s Director and CEO Alvaro Torres said, “Our initial export to the Brazilian market represents an important first step toward opening a large, underserved market where patients face high barriers to access. By providing patients with affordable high-quality products, and an unparalleled patient experience, we see an opportunity to disrupt the Brazilian market and deliver on our mission of improving patients lives. Khiron is already treating thousands of patients in Colombia, Peru, UK and Germany, with positive outcomes. In due course, we plan to bring our successful Zerenia clinic model to Brazil, as we have done in Peru and Colombia.”

So far, the company has created two partnerships in Brazil to enhance medical cannabis education and awareness for care providers across the country. Khiron has an exclusive distribution agreement with Medlive. Also, the company entered a marketing contract with a medical distributor, TAIMIN.

Khiron expanding to Mexico

The company is accelerating its entry into Mexico, where there is a large market for around 11.7 million patients in need of medical cannabis remedies. Khiron is leveraging the National Strategic project designation in Columbia for authorization to include Mexico as a destination within the international export quota. There more than 700 kg of high-THC extract available for export to Mexico. Already the company has finalized a manufacturing and distribution agreement for medical cannabis products in Mexico. The company will launch Zerenia clinics in major Mexican cities in 2021, replicating the vertically integrated model in Peru and Columbia. 

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories